Autonomic Pharmacology--Introduction-Lecture II, slide 1

press above to begin the lecture

 

return to Pharmacology Table of Contents

Table of Contents
  • ANS Anatomy
    • Autonomic and Somatic Innervation
    • Autonomic Reflex Arc
    • Autonomic Reflex Arc: First Link
    • Sensory Fiber Neurotransmitter(s)
    • Autonomic Nervous System Neurotransmitters: Summary
    • CNS and the Autonomic Nervous System
      • Spinal Cord Reflexes
      • Hypothalamus and Nucleus tractus solitarii
      • Higher Centers
    • Peripheral ANS Divisions
  • Comparison between Sympathetic & Parasympathetic Systems
  • Sympathetic Nervous System Anatomy
    • Diagram Sympathetic System
    • Anatomical Outline
      • Paravertebral Ganglia
      • Prevertebral Ganglia
      • Terminal Ganglia
      • Adrenal Medulla
  • Parasympathetic System Anatomy
  • ANS Neurotransmitter Effector Organs
  • Eye
  • Heart
  • Arterioles
  • Systemic Veins
  • Lung

 

  • Skin
  • Adrenal Medulla
  • Skeletal Muscle
  • Liver
  • Posterior Pituitary

 

  • Interactions between Sympathetic & Parasympathetic Systems
  • "Fight or Flight": Characteristics of the ANS
  • ANS Neurotransmission
    • Neurotransmitter Criteria
    • Neurotransmission Steps:
      • Axonal Conduction
      • Storage and Release of Neurotransmitter
      • Combination of Neurotransmitter and Post-Junctional Receptors
      • Termination of Neurotransmitter Action
      • Other Non-electrogenic Functions
    • Cholinergic Neurotransmission
      • Transmitter Synthesis and Degradation
      • Acetylcholinesterase
      • Acetylcholine: Storage and Release
      • Site Differences:
        • Skeletal Muscle
        • Autonomic Effectors
        • Autonomic Ganglia
        • Blood vessels
      • Signal Transduction: Receptors
  • Adrenergic Transmitters: Biosynthetic Pathways
  • Adrenergic Neurotransmission: Introduction to the Neurotransmitters
  • Catecholamine Synthesis, Storage, Release and Reuptake
    • Enzymes
    • Catecholamine storage
    • Regulation of adrenal medullary catecholamine levels
    • Reuptake
    • Metabolic Transformation
    • Indirect-acting sympathomimetics
    • Release
  • Adrenergic Receptor Subtypes
    • ß-adrenergic receptors
    • Alpha-adrenergic receptors
    • Catecholamine Refractoriness
  • Other Autonomic Neurotransmitters
    • Co-transmission
      • ATP
      • VIP
      • Neuropeptide Y family
    • Purines
    • Nitric Oxide (Modulator)
  • Predominant Sympathetic/Parasympathetic Tone
  • Baroreceptor Reflexes
  • Pharmacological Modification of Autonomic Function
  • Autonomic Dysfunction

 

Catecholamine Refractoriness
  • Following exposure to catecholamines, there is a progressive loss of the ability of the target site to respond to catecholamines. This phenomenon is termed tachyphylaxis, desensitization or refractoriness.
  • Regulation of catecholamine responsiveness occurs at several levels:
Receptors G proteins Adenyl cyclase Cyclic nucleotide phosphodiesterase
  • Stimulation of ß-adrenergic receptors rapidly causes receptor phosphorylation and decreased responsiveness. The phosphorylated receptor exhibits:
    • decreased coupling to Gs and
    • decreased stimulation of adenylyl cyclase.

Return to Table of Contents

 

Lefkowitz, R.J, Hoffman, B.B and Taylor, P. Neurotransmission: The Autonomic and Somatic Motor Nervous Systems, In, Goodman and Gillman's The Pharmacologial Basis of Therapeutics,(Hardman, J.G, Limbird, L.E, Molinoff, P.B., Ruddon, R.W, and Gilman, A.G.,eds) TheMcGraw-Hill Companies, Inc.,1996, pp.112-137.
Hoffman, B. B. Adrenoceptor-Activating & Other Sympathomimetic Drugs: Introduction to Antimicrobial Agents in Basic and Clinical Pharmacology, (Katzung, B. G., ed) Appleton-Lange, 1998, p.118-122

Other Autonomic Neurotransmitters/Cotransmitters

  • ATP

    • ATP and catecholamines are found together in neuronal and adrenal medullary storage granules. ATP is released along with transmitters and, in certain cases, has an important role in synaptic transmission.

  • Vasoactive Intestinal Peptide (VIP)

    • Vasoactive intestinal peptide (VIP) is found in association with ACh in autonomic parasympathetic fibers innervating blood vessels and exocrine glands and cholinergic sympathetic fibers innervating sweat glands.

    • VIP may be involved in salivation, tracheal and the GI tract responsiveness to parasympathetic input.

  • Neuropeptide Y Family

    • The neuropeptide Y family includes NPY, pancreatic polypeptide, and peptide YY.

    • NPY in the periphery is associated with sympathetic fibers and assists in maintaining vascular tone.

    • NPY is a potent, long-lasting vasoconstrictor, especially of small vessels

  • Purines

    • Purines such as ATP and adenosine may be responsible for apparent non-cholinergic, non-adrenergic autonomic neurotransmission.

  • Nitric Oxide

    • Blood vessel endothelium is required for ACh-mediated smooth muscle relaxation.

    • The endothelial cell layer modulates vessel responsiveness to autonomic and hormonal influences.

    • Endothelial cell elaborate endothelium-derived relaxing factor (EDRF, nitric oxide) and a contracting factor.

    • Pharmacological actions of serotonin, histamine, bradykinin, purines, thrombin are mediated to some degree by stimulation of EDRF release.

    • Endothelial-released nitric oxide diffuses into vascular smooth muscle and activates guanylyl cyclase which increases cGMP.

    • Clinically, hypotension associated with endotoxemia may be mediated partially by increased release of nitric oxide. A similar mechanism is proposed for hypotension induced by cytokines.

      • The vascular response is due to endothelial cell nitric oxide (NO) release following agonist interactions with endothelial muscarinic receptors.

      • Increased NO activates guanylate cyclase which increases cyclic GMP concentrations.

      • Subsequent activation of a Ca2+ ion pump reduces intracellular Ca2+.

      • Reduction in intracellular Ca2+ causes vascular smooth muscle relaxation.

        • Ca2+ complexes with calmodulin activating light-chain myosin kinase

        • Increased cGMP promotes dephosphorylation of myosin light-chains.

        • Smooth-muscle myosin must be phosphorylated in order to interact with actin and cause muscle contraction.

Return to Table of Contents

 

Predominant Sympathetic or Parasympathetic Tone

Antatomical Site

Predominant Autonomic Tone

Arterioles

Sympathetic-adrenergic

Veins

Sympathetic-adrenergic

Heart

Parasympathetic-cholinergic

Ciliary Muscle

Parasympathetic-cholinergic

Gastrointestinal Tract

Parasympathetic-cholinergic

Salivary Glands

Parasympathetic-cholinergic

Sweat Glands

Sympathetic-cholinergic

Taylor, P. Agents Acting at the Neuromuscular Junction and Autonomic Ganglia In, Goodman and Gillman's The Pharmacologial Basis of Therapeutics,(Hardman, J.G, Limbird, L.E, Molinoff, P.B., Ruddon, R.W, and Gilman, A.G.,eds) The McGraw-Hill Companies, Inc.,1996, pp.193-195. Adapted from Table 9-3

Return to Table of Contents

 

Baroreceptor Reflexes
  • A principal mechanism for arterial blood pressure control is the baroreceptor reflex.
  • The reflex is initiated by activation of stretch receptors located in the wall of most large arteries of the chest and neck.
  • A high density of baroreceptors is found in the wall of each internal carotid artery (just above the carotid bifurcation i.e. carotid sinus) and in the wall of the aortic arch.

 As pressure rises and especially for rapid increases in pressure:

  • baroreceptor input to the tractus solitarius of the medulla results in inhibition of the vasoconstrictor center and excitation of the vagal (cholinergic) centers resulting in:
  1. a vasodilatation of the veins and arterioles in the peripheral vascular beds.
  2. negative chronotropic and inotropic effects on the heart. (slower heart rate with reduced force of contraction)

 

Return to Table of Contents

 

Pharmacological Modification of Autonomic Function

 

Return to Table of Contents

Transmitter Synthesis: Site 1

Cholinergic
  • Hemicholinium (HC-3) blocks the choline transport system into the nerve ending, thus limiting acetylcholine (ACh) synthesis.

 

Adrenergic
  • Alpha-methyltyrosine inhibits tyrosine hydroxylase thus preventing synthesis of norepinephrine.

  • Methyldopa inhibits aromatic amino acid decarboxylase and is itself decarboxylated and hydroxylated to form the "false transmitter" alpha-methyl norepinephrine

Return to Table of Contents

Return to Table of Contents

 

Transmitter Release: Site 2

Cholinergic
  • Botulinum toxin can be used clinically to treat ocular muscle spasms, muscle dystonias, and spasms.
  • Botulinus toxin binding at a presynaptic site blocks ACh release.
  • Vesamicol blocks ACh transport into storage vesicles, thus limiting release.

 

Adrenergic
  • Bretylium and guanethidine prevent action-potential mediated norepinephrine release.
  • Transient release may occur with these agents because they displace norepinephrine from storage sites.
  • Tyramine, amphetamine, and ephedrine can produce a brief liberation of transmitter.
  • Reserpine, by inhibiting vesicular uptake, produces a slow, depletion of norepinephrine, ultimately causing adrenergic blockade. Cytoplasmic MAO metabolizes the neurotransmitter.
  • Reserpine similarly depletes dopamine and serotonin. Physiological effects of reserpine are due to depletion of many transmitters.

Return to Table of Contents

 

Receptor Interactions: Site 3

Cholinergic
  • Tetraethylammonium, trimethaphan and hexamethonium are nicotinic ganglionic antagonists.
  • Decamethonium, a depolarizing drug, selectively causes neuromuscular blockade.
  • All classes of muscarinic receptors are blocked by atropine.

 

Adrenergic
  •  Phenylephrine (Neo-Synephrine):  an alpha1 receptor agonist.
  •  Clonidine (Catapres): an alpha2 receptor agonist.
  •  Prazosin (Minipress): an example of an alpha1 receptor antagonist.
  •  Yohimbine (Yocon): an example of an alpha2 receptor antagonist.
  •  Isoproterenol (Isuprel): ß1 and ß2 receptor agonist.
  •  Dobutamine (Dobutrex):  a relatively selective myocardial ß1 receptor agonist.
  •  Terbutaline (Brethine):  relatively selective ß2 receptor agonist.
  •  Propranolol (Inderal):  an example of a non-selective beta-adrenergic receptor blocker.
  •  Metoprolol (Lopressor):  an example of a relatively selective ß1 receptor antagonist.

Return to Table of Contents

 

Termination of Transmitter Effects: Site 4

Cholinergic
  • Acetylcholinesterase inhibitors prevent breakdown and inactivation of acetylcholine.
    • ACh accumulation at the neuromuscular junction causes flacid paralysis.
    • ACh accumulation at postganglionic muscarinic sites results in either excessive stimulation (contraction & secretion) or inhibition (hyperpolarization), depending on the site.
    • ACh accumulation at autonomic ganglia cause increased transmission.

 

Adrenergic
  • Interference with neurotransmitter reuptake results in potentiation of catecholamine effects.
  • Cocaine and imipramine are examples of drugs that inhibit the reuptake system.
  • Monoamine oxidase (MAO) inhibitors potentiate actions of tyramine; whereas catechol-O-methyl transferase (COMT) inhibitors (pyrogallol and tropolone) only slightly increase catecholamine effects.

Return to Table of Contents

 

 press the purple arrow below (right) to go to the next page